200 related articles for article (PubMed ID: 31874825)
1. Design and synthesis of a novel BODIPY-labeled PSMA inhibitor.
Son SH; Kwon H; Ahn HH; Nam H; Kim K; Nam S; Choi D; Ha H; Minn I; Byun Y
Bioorg Med Chem Lett; 2020 Feb; 30(3):126894. PubMed ID: 31874825
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
Wang S; Blaha C; Santos R; Huynh T; Hayes TR; Beckford-Vera DR; Blecha JE; Hong AS; Fogarty M; Hope TA; Raleigh DR; Wilson DM; Evans MJ; VanBrocklin HF; Ozawa T; Flavell RR
Mol Pharm; 2019 Sep; 16(9):3831-3841. PubMed ID: 31381351
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and Evaluation of Multifunctional Fluorescent Inhibitors with Synergistic Interaction of Prostate-Specific Membrane Antigen and Hypoxia for Prostate Cancer.
Kwon YD; Oh JM; La MT; Chung HJ; Lee SJ; Chun S; Lee SH; Jeong BH; Kim HK
Bioconjug Chem; 2019 Jan; 30(1):90-100. PubMed ID: 30485073
[TBL] [Abstract][Full Text] [Related]
4. In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe.
Mazzocco C; Fracasso G; Germain-Genevois C; Dugot-Senant N; Figini M; Colombatti M; Grenier N; Couillaud F
Sci Rep; 2016 Mar; 6():23314. PubMed ID: 26996325
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and Biological Evaluation of PSMA Ligands with Aromatic Residues and Fluorescent Conjugates Based on Them.
Machulkin AE; Shafikov RR; Uspenskaya AA; Petrov SA; Ber AP; Skvortsov DA; Nimenko EA; Zyk NU; Smirnova GB; Pokrovsky VS; Abakumov MA; Saltykova IV; Akhmirov RT; Garanina AS; Polshakov VI; Saveliev OY; Ivanenkov YA; Aladinskaya AV; Finko AV; Yamansarov EU; Krasnovskaya OO; Erofeev AS; Gorelkin PV; Dontsova OA; Beloglazkina EK; Zyk NV; Khazanova ES; Majouga AG
J Med Chem; 2021 Apr; 64(8):4532-4552. PubMed ID: 33822606
[TBL] [Abstract][Full Text] [Related]
6.
Banerjee SR; Foss CA; Horhota A; Pullambhatla M; McDonnell K; Zale S; Pomper MG
Biomacromolecules; 2017 Jan; 18(1):201-209. PubMed ID: 28001364
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and
Cordonnier A; Boyer D; Besse S; Valleix R; Mahiou R; Quintana M; Briat A; Benbakkar M; Penault-Llorca F; Maisonial-Besset A; Maunit B; Tarrit S; Vivier M; Witkowski T; Mazuel L; Degoul F; Miot-Noirault E; Chezal JM
J Mater Chem B; 2021 Sep; 9(36):7423-7434. PubMed ID: 34373887
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of PSMA/hepsin-targeted heterobivalent ligands.
Subedi M; Minn I; Chen J; Kim Y; Ok K; Jung YW; Pomper MG; Byun Y
Eur J Med Chem; 2016 Aug; 118():208-218. PubMed ID: 27128184
[TBL] [Abstract][Full Text] [Related]
10. (
Duan X; Liu F; Kwon H; Byun Y; Minn I; Cai X; Zhang J; Pomper MG; Yang Z; Xi Z; Yang X
J Med Chem; 2020 Apr; 63(7):3563-3576. PubMed ID: 32207938
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy.
Umbricht CA; Benešová M; Schibli R; Müller C
Mol Pharm; 2018 Jun; 15(6):2297-2306. PubMed ID: 29684274
[TBL] [Abstract][Full Text] [Related]
12. Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate.
Liu T; Nedrow-Byers JR; Hopkins MR; Wu LY; Lee J; Reilly PT; Berkman CE
Bioorg Med Chem Lett; 2012 Jun; 22(12):3931-4. PubMed ID: 22607680
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.
Chen Y; Pullambhatla M; Banerjee SR; Byun Y; Stathis M; Rojas C; Slusher BS; Mease RC; Pomper MG
Bioconjug Chem; 2012 Dec; 23(12):2377-85. PubMed ID: 23157641
[TBL] [Abstract][Full Text] [Related]
14. Design of a Small-Molecule Drug Conjugate for Prostate Cancer Targeted Theranostics.
Kumar A; Mastren T; Wang B; Hsieh JT; Hao G; Sun X
Bioconjug Chem; 2016 Jul; 27(7):1681-9. PubMed ID: 27248781
[TBL] [Abstract][Full Text] [Related]
15. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and pre-clinical evaluation of a new class of high-affinity
Kelly J; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Ponnala S; Babich JW
Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):647-661. PubMed ID: 27847991
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preliminary evaluation of
Vaidyanathan G; Mease RC; Minn I; Choi J; Chen Y; Shallal H; Kang CM; McDougald D; Kumar V; Pomper MG; Zalutsky MR
Nucl Med Biol; 2021; 94-95():67-80. PubMed ID: 33601187
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer.
Kularatne SA; Thomas M; Myers CH; Gagare P; Kanduluru AK; Crian CJ; Cichocki BN
Clin Cancer Res; 2019 Jan; 25(1):177-187. PubMed ID: 30201762
[TBL] [Abstract][Full Text] [Related]
20. Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody.
Lütje S; Rijpkema M; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
J Nucl Med; 2014 Jun; 55(6):995-1001. PubMed ID: 24700882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
